Skip to main content Skip to footer
Algernon Pharmaceuticals Inc.
  • Home
  • Home
  • About
    • Overview
    • Management Team
    • Board of Directors
    • Medical & Scientific Advisors
  • Alzheimer’s
    • Overview
    • AD Clinics
    • Markets
    • Resources
  • Pipeline
    • Overview
    • NP-251 (Repirinast)
    • AP-188 (DMT)
  • Companies
    • Algernon NeuroScience
  • News & Media
    • News Releases
    • IR Calendar
    • Presentations
    • Videos/Articles
  • Investors
    • Overview
    • News & Events
    • Company Info
    • Financial Info
    • Stock Data
    • SEDAR
    • Governance
  • Contact

News Releases

Apr 04, 2019 7:00am EDT

Algernon Pharmaceuticals Appoints Leading Inflammatory Bowel Disease Expert Dr. Walter Reinisch to Its Medical and Scientific Advisory Board

Apr 01, 2019 7:00am EDT

Algernon Pharmaceuticals Announces Reduction of Key Secondary Marker of Fibrosis in Pre-Clinical NASH Study

Mar 21, 2019 7:00am EDT

Algernon Pharmaceuticals Appoints Leading Liver Disease Expert Dr. Arun Sanyal to Its Medical and Scientific Advisory Board

Mar 12, 2019 11:46pm EDT

Algernon Retains Renmark Financial Communications

Feb 25, 2019 7:00am EST

Algernon Pharmaceuticals Expands Its Research Program to Include Idiopathic Pulmonary Fibrosis

Feb 19, 2019 7:00am EST

Algernon Pharmaceuticals Begins Trading on The CSE Under The Symbol AGN

  • Previous Pagearrow_back
  • Page 1…
  • …
  • Page 13
  • Page 14
  • Page 15
  • Page 16
  • Page 17
  • Page 18
  • Page 19
  • Page 20
  • Page 21
  • Page 22
rss_feed News RSS
  • Visit us on Facebook

    Facebook

  • Visit us on Twitter

    Twitter

  • Visit us on LinkedIn

    LinkedIn

  • Email Alerts
©2025 Algernon Pharmaceuticals Inc. All Rights Reserved.
Privacy Policy Sitemap